STUDY OF THE COMBINATION OF VELCADE, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE OR RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMA: